Launched by a consortium of NYC-based academic medical centers including MSK, Mount Sinai and Montefiore, New York State’s first and only proton center is now one of the nation’s leading providers of advanced radiotherapy
NYPC has grown faster than any other proton center in the US, reaching an industry-record milestone of 1,500 patients treated in two years despite the challenges of COVID-19
New York, NY, August 18, 2021 — The New York Proton Center (NYPC) today celebrates its two-year anniversary since beginning patient treatment in August 2019.
Located in East Harlem, NYPC remains New York State’s only facility for proton therapy, an advanced form of cancer radiotherapy that targets cancerous tumors with millimeter precision while minimizing damage to surrounding organs and tissues.
Launched by a unique consortium of renowned NYC-based cancer providers including Memorial Sloan Kettering Cancer Center (MSK), Montefiore Health System, and Mount Sinai Health System in 2019, NYPC is one of just 38 proton centers in the United States providing this innovative radiotherapy treatment.
During its first two years of operation, the center has addressed a significant, unmet need for advanced radiotherapy to treat complex cancer conditions in New York State.
“Our success over the past two years is a testament to the vision of three world-class clinical partners that came together to create this facility. We’ve shown that a collaborative approach can yield tremendous results—for New Yorkers, patients across the tri-state region, and beyond,” said Jonathan Weinbach, CEO of the New York Proton Center. “Two years in, we’re committed to continued clinical excellence and leading the industry in advancing the science of radiotherapy treatment.”
“Since 2019, the New York Proton Center has led a pivotal shift in cancer treatment in the Tri-State region,” said Dr. Charles B. Simone, FACRO, Chief Medical Officer of the New York Proton Center. “I could not be more grateful to the faculty and staff of NYPC and to our partner institutions, who have worked diligently throughout the pandemic to provide the highest quality care to as many patients as possible. I look forward to extending our reach to even more patients as we prioritize making proton therapy an industry standard.”
Persevering through the challenges of a pandemic that arrived only seven months after opening its doors to patients, NYPC rapidly grew to become one of the busiest proton centers in the country. The center has treated nearly 1,500 patients at an industry record-setting pace within its first two years of operation. Nearly 75 percent of those patients have come from the tri-state region.
NYPC’s highly experienced clinical care team treats a wide range of cancers—including complex brain, head and neck, breast, lung, gastrointestinal, prostate, and pediatric cancers—for which proton therapy has proven highly effective in reducing side effects and improving quality of life for patients.
The New York Proton Center is part of the ongoing commercial and residential redevelopment of the area surrounding East 125th Street in Harlem. The $300 million state-of-the-art facility is part of the City’s ongoing effort to position healthcare-based economic development projects as a cornerstone of its infrastructure-led recovery.
About the New York Proton Center
The New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.
For additional information, please visit www.nyproton.com.
